{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:13:25Z","timestamp":1790162005456,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,8,15]]},"DOI":"10.1093\/infdis\/jiu139","type":"journal-article","created":{"date-parts":[[2014,3,9]],"date-time":"2014-03-09T01:25:13Z","timestamp":1394328313000},"page":"517-534","source":"Crossref","is-referenced-by-count":54,"title":["Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16\/18 Antibodies: Analysis of the Control Arm of PATRICIA"],"prefix":"10.1093","volume":"210","author":[{"given":"Xavier","family":"Castellsagu\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Naud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Nan","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosette M.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Julieta V.","family":"Germar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Lehtinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorma","family":"Paavonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unnop","family":"Jaisamrarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"Garland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Salmer\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Apter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Kitchener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Rachel","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genara","family":"Limson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Szarewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Romanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred Y.","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tino F.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy A. J.","family":"Poppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Xavier","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Newton S.","family":"de Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebren A. A.","family":"Tjalma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboobeh","family":"Safaeian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Raillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Struyf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Dubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Rosillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Baril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,3,8]]},"reference":[{"key":"key\n\t\t\t\t20170511121743_JIU139C1","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional survey","volume":"11","year":"2010","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20170511121743_JIU139C2","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years","volume":"374","author":"The GlaxoSmithKline Vaccine HPV-007 Study Group","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170511121743_JIU139C3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170511121743_JIU139C4","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170511121743_JIU139C5","first-page":"1916","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"The FUTURE II Study Group","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170511121743_JIU139C6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20170511121743_JIU139C7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/jnci\/86.7.494","article-title":"A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16","volume":"86","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20170511121743_JIU139C8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1128\/CDLI.4.2.122-126.1997","article-title":"Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women","volume":"4","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"key\n\t\t\t\t20170511121743_JIU139C9","first-page":"336","article-title":"Serum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types","volume":"4","year":"2013","journal-title":"J Clin Virol"},{"key":"key\n\t\t\t\t20170511121743_JIU139C10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/1471-2334-10-238","article-title":"Determinants of seropositivity among HPV-16\/18 DNA positive young women","volume":"10","year":"2010","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20170511121743_JIU139C11","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/jmv.23664","article-title":"Association of HPV types 6, 11, 16, and 18 DNA detection and serological response in unvaccinated adolescent women","volume":"85","year":"2013","journal-title":"J Med Virol"},{"key":"key\n\t\t\t\t20170511121743_JIU139C12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1099\/0022-1317-80-2-391","article-title":"Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study","volume":"80","year":"1999","journal-title":"J Gen Virol"},{"key":"key\n\t\t\t\t20170511121743_JIU139C13","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","volume":"181","year":"2000","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170511121743_JIU139C14","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1086\/517428","article-title":"Stability over time of serum antibody levels to human papillomavirus type 16","volume":"177","year":"1998","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170511121743_JIU139C15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1055-9965.EPI-03-0166","article-title":"Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica","volume":"13","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key\n\t\t\t\t20170511121743_JIU139C16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/1055-9965.283.14.1","article-title":"Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women","volume":"14","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key\n\t\t\t\t20170511121743_JIU139C17","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","year":"2009","journal-title":"Hum Vaccin"},{"key":"key\n\t\t\t\t20170511121743_JIU139C18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/00365540903501608","article-title":"Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes","volume":"42","year":"2010","journal-title":"Scand J Infect Dis"},{"key":"key\n\t\t\t\t20170511121743_JIU139C19","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/342972","article-title":"Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles","volume":"186","year":"2002","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170511121743_JIU139C20","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/jnci\/djq384","article-title":"Epidemiological study of anti-HPV16\/18 seropositivity and subsequent risk of HPV16 and -18 infections","volume":"102","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20170511121743_JIU139C21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/infdis\/jir209","article-title":"A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste natural history study","volume":"204","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170511121743_JIU139C22","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170511121743_JIU139C23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","year":"2012","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20170511121743_JIU139C24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","year":"2012","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20170511121743_JIU139C25","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1128\/JCM.00539-06","article-title":"Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR","volume":"44","year":"2006","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170511121743_JIU139C26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4161\/hv.4.6.6912","article-title":"Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16\/18 cervical cancer vaccine","volume":"4","year":"2008","journal-title":"Human Vacc"},{"key":"key\n\t\t\t\t20170511121743_JIU139C27","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ygyno.2012.08.033","article-title":"Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial","volume":"127","year":"2012","journal-title":"Gynecol Oncol"},{"key":"key\n\t\t\t\t20170511121743_JIU139C28","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/ijc.25675","article-title":"Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33","volume":"128","year":"2011","journal-title":"Int J Cancer"},{"key":"key\n\t\t\t\t20170511121743_JIU139C29","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial","volume":"6","year":"2013","journal-title":"Cancer Prev Res"},{"key":"key\n\t\t\t\t20170511121743_JIU139C30","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4161\/hv.18865","article-title":"Sustained immunogenicity and efficacy of the HPV-16\/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up","volume":"8","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"key\n\t\t\t\t20170511121743_JIU139C31","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/OLQ.0b013e3181e1a2c5","article-title":"Seroprevalence and correlates of human papillomavirus 16\/18 seropositivity among young women in Costa Rica","volume":"37","author":"for the Costa Rica HPV Vaccine Trial (CVT) Group","year":"2010","journal-title":"Sex Transm Dis"},{"key":"key\n\t\t\t\t20170511121743_JIU139C32","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/infdis\/174.5.927","article-title":"The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women","volume":"174","year":"1996","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170511121743_JIU139C33","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1055-9965.EPI-09-1235","article-title":"Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women","volume":"19","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key\n\t\t\t\t20170511121743_JIU139C34","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1086\/599988","article-title":"Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials","volume":"200","year":"2009","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170511121743_JIU139C35","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1158\/1055-9965.EPI-12-0558","article-title":"Direct comparison of HPV16 serological assays used to define HPV-naive women in HPV vaccine trials","volume":"21","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T01:46:23Z","timestamp":1689039983000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article-lookup\/doi\/10.1093\/infdis\/jiu139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,8]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,3,8]]},"published-print":{"date-parts":[[2014,8,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiu139","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,8]]}}}